Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | See Remarks | December 05, 2025 | December 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date December 05, 2025 · Filed December 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,348 |
Reported balance
After 2025-12-05 transaction · row 1
1 source rowRow 1 · 2025-12-05 · Sale · Disposed 542 · Balance 16,348 F1: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 23, 2022 and November 22, 2023, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 23, 2022 and November 22, 2023, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2025 Filed Dec 5, 2025 23:47 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 542 | $14.23 | $7,712.66 |
DisclosureSEC source: 0002064832-25-000067 · form4.xml · nonDerivative · entry 1 Trout Harry R. III · CIK 0002085123 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,348 F1 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 23, 2022 and November 22, 2023, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:05 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 380 | $13.96 | $5,304.80 |
DisclosureSEC source: 0002064832-25-000050 · form4.xml · nonDerivative · entry 2 Trout Harry R. III · CIK 0002085123 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,890 F2 · shares: Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 27, 2024, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:05 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 105 | $14.12 | $1,482.60 |
DisclosureSEC source: 0002064832-25-000050 · form4.xml · nonDerivative · entry 1 Trout Harry R. III · CIK 0002085123 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,270 F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 12,925 | $0.00 Strike: $13.66 | $0.00 |
DisclosureSEC source: 0002064832-25-000036 · form4.xml · derivative · entry 2 Trout Harry R. III · CIK 0002085123 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,925 Underlying: Common Stock · 12,925 shares Expires 2035-11-25 F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025). Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 22:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 6,463 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-25-000036 · form4.xml · nonDerivative · entry 1 Trout Harry R. III · CIK 0002085123 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,375 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 1, 2026 and in substantially equal annual installments over the next three anniversaries thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.